IL284073B2 - תרכובת הטרוציקלית ומלח שלה, תרופה, והתרכובת או המלח לשימוש במניעת או בטיפול בנרקולפסיה - Google Patents

תרכובת הטרוציקלית ומלח שלה, תרופה, והתרכובת או המלח לשימוש במניעת או בטיפול בנרקולפסיה

Info

Publication number
IL284073B2
IL284073B2 IL284073A IL28407321A IL284073B2 IL 284073 B2 IL284073 B2 IL 284073B2 IL 284073 A IL284073 A IL 284073A IL 28407321 A IL28407321 A IL 28407321A IL 284073 B2 IL284073 B2 IL 284073B2
Authority
IL
Israel
Prior art keywords
group
alkyl
optionally substituted
compound
salt
Prior art date
Application number
IL284073A
Other languages
English (en)
Other versions
IL284073A (he
IL284073B1 (he
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69770989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL284073(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of IL284073A publication Critical patent/IL284073A/he
Publication of IL284073B1 publication Critical patent/IL284073B1/he
Publication of IL284073B2 publication Critical patent/IL284073B2/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
IL284073A 2019-01-31 2020-01-30 תרכובת הטרוציקלית ומלח שלה, תרופה, והתרכובת או המלח לשימוש במניעת או בטיפול בנרקולפסיה IL284073B2 (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019015488 2019-01-31
PCT/JP2020/004444 WO2020158958A1 (en) 2019-01-31 2020-01-30 Heterocyclic compound and use thereof

Publications (3)

Publication Number Publication Date
IL284073A IL284073A (he) 2021-08-31
IL284073B1 IL284073B1 (he) 2025-03-01
IL284073B2 true IL284073B2 (he) 2025-07-01

Family

ID=69770989

Family Applications (1)

Application Number Title Priority Date Filing Date
IL284073A IL284073B2 (he) 2019-01-31 2020-01-30 תרכובת הטרוציקלית ומלח שלה, תרופה, והתרכובת או המלח לשימוש במניעת או בטיפול בנרקולפסיה

Country Status (32)

Country Link
US (7) US20230040770A1 (he)
EP (2) EP3917616B1 (he)
JP (2) JP7253640B2 (he)
KR (1) KR102882779B1 (he)
CN (6) CN118271298A (he)
AR (1) AR117916A1 (he)
AU (1) AU2020215380B2 (he)
BR (1) BR112021014180A2 (he)
CA (1) CA3124536A1 (he)
CL (1) CL2021001973A1 (he)
CO (1) CO2021011188A2 (he)
DK (1) DK3917616T3 (he)
EA (1) EA202192138A1 (he)
EC (1) ECSP21056325A (he)
ES (1) ES3037650T3 (he)
FI (1) FI3917616T3 (he)
HR (1) HRP20250785T1 (he)
HU (1) HUE071890T2 (he)
IL (1) IL284073B2 (he)
LT (1) LT3917616T (he)
MX (1) MX2021008241A (he)
MY (1) MY209784A (he)
PE (1) PE20211700A1 (he)
PH (1) PH12021551846A1 (he)
PL (1) PL3917616T3 (he)
PT (1) PT3917616T (he)
RS (1) RS67170B1 (he)
SG (1) SG11202106791XA (he)
SI (1) SI3917616T1 (he)
TW (1) TWI832962B (he)
WO (1) WO2020158958A1 (he)
ZA (1) ZA202106304B (he)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019027058A1 (en) * 2017-08-03 2019-02-07 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND AND USE THEREOF
IL284073B2 (he) 2019-01-31 2025-07-01 Takeda Pharmaceuticals Co תרכובת הטרוציקלית ומלח שלה, תרופה, והתרכובת או המלח לשימוש במניעת או בטיפול בנרקולפסיה
CN114761412B (zh) 2019-11-25 2024-10-11 阿尔克姆斯有限公司 取代的大环化合物和相关治疗方法
US12448377B2 (en) 2019-11-27 2025-10-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
MX2023001840A (es) 2020-08-18 2023-03-13 Merck Sharp & Dohme Llc Agonistas de bicicloheptano pirrolidina de los receptores de orexina.
CN116583502A (zh) * 2020-09-03 2023-08-11 欧瑞夏治疗有限公司 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途
WO2022051583A1 (en) * 2020-09-03 2022-03-10 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists
JP2022064180A (ja) * 2020-10-13 2022-04-25 武田薬品工業株式会社 複素環化合物
CA3196901A1 (en) * 2020-11-02 2022-05-05 Kira A. Armacost Macrocyclic urea orexin receptor agonists
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
WO2022207935A1 (en) * 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
MX2023011669A (es) 2021-04-02 2023-10-18 Takeda Pharmaceuticals Co Uso de un agonista del receptor de orexina 2 para la recuperacion posoperatoria.
CN119110802A (zh) 2022-03-01 2024-12-10 森特萨制药(英国)有限公司 中环或大环苄基取代的杂环衍生物和相关用途
WO2023199091A1 (en) 2022-04-12 2023-10-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP4600242A1 (en) 2022-10-07 2025-08-13 Kissei Pharmaceutical Co., Ltd. Cyclopentane compound
EP4611745A1 (en) 2022-10-31 2025-09-10 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
CN120322433A (zh) 2022-10-31 2025-07-15 武田药品工业株式会社 杂环化合物
KR20250105712A (ko) 2022-11-30 2025-07-08 다케다 야쿠힌 고교 가부시키가이샤 헤테로사이클릭 화합물 및 이의 용도
KR20250112793A (ko) 2022-12-16 2025-07-24 다이이찌 산쿄 가부시키가이샤 2-아자비시클로[3.1.1]헵탄 화합물
AR132145A1 (es) 2023-03-16 2025-05-28 Takeda Pharmaceuticals Co Compuestos heterocíclicos macrocíclicos y sus usos
TW202502342A (zh) * 2023-06-02 2025-01-16 日商武田藥品工業股份有限公司 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑
GB202404750D0 (en) 2024-04-03 2024-05-15 Bial Portela & Ca Sa Orexin receptor agonists
WO2025211415A1 (ja) * 2024-04-04 2025-10-09 キッセイ薬品工業株式会社 置換スルホンアミド化合物
WO2025211416A1 (ja) * 2024-04-04 2025-10-09 キッセイ薬品工業株式会社 置換スルホンアミド大環状化合物
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
WO2025229494A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2025229495A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2025229493A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
WO2025229584A2 (en) * 2024-05-01 2025-11-06 Takeda Pharmaceutical Company Limited Orexin receptor 2 (ox2r) agonist for use in narcolepsy type 1 (nt1)
WO2026017128A1 (zh) * 2024-07-17 2026-01-22 江苏恩华药业股份有限公司 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途
WO2026019302A1 (ko) * 2024-07-18 2026-01-22 (주)셀트리온 신규한 오렉신 2 수용체 작용제 및 이의 용도

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1028305A (en) 1911-03-04 1912-06-04 Nicholas King Turnbull Machine for remaking wire-drawing dies.
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
AU5773500A (en) 1999-06-28 2001-01-31 Board Of Trustees Of The University Of Illinois, The Inhibitors of memapsin 2 and use thereof
EP1252329A4 (en) 1999-07-30 2004-12-22 Univ Leland Stanford Junior HYPOKRETIN AND HYPOKRETINRECEPTORS FOR THE REGULATION OF SLEEP AND RELATED DISORDERS
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US7112566B1 (en) 1999-09-17 2006-09-26 The Regents Of The University Of California Systemic administration of Hypocretin-1
AU2001251306A1 (en) 2000-04-04 2001-10-15 Siegel, Jerome M. Treatment of sleep disorders with hypocretin-1
US20080260744A1 (en) 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
WO2004040000A2 (en) 2002-09-09 2004-05-13 Nura, Inc G protein coupled receptors and uses thereof
US7618786B2 (en) 2002-12-13 2009-11-17 Janssen Pharmaceutica N.V. Method for identifying modulators of human orexin-2 receptor
HUP0304101A3 (en) * 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
AR060462A1 (es) 2006-04-14 2008-06-18 Abbott Gmbh & Co Kg Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3
AU2012200270A1 (en) * 2007-05-23 2012-02-09 Merck Sharp & Dohme Corp. Pyridyl piperidine orexin receptor antagonists
US20110053859A1 (en) 2007-10-10 2011-03-03 The U. S. Government Respresented by the Department of Veterans Affairs Methods to reduce the effects of sleep deprivation
RU2010140682A (ru) 2008-03-05 2012-04-10 Пэрэтек Фамэсьютикэлс, Инк. (US) Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
WO2012137982A2 (en) * 2011-04-05 2012-10-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
TW201341380A (zh) * 2012-04-05 2013-10-16 Takeda Pharmaceutical 磺醯胺衍生物及其用途
JP6244365B2 (ja) 2012-10-10 2017-12-06 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ［オルトビ−（ヘテロ−）アリール］−［２−（メタビ−（ヘテロ−）アリール）−ピロリジン−１−イル］−メタノン誘導体であるオレキシン受容体アンタゴニスト
WO2014170343A1 (en) 2013-04-15 2014-10-23 Icm (Institut Du Cerveau Et De La Moelle Épinière) Depolarizing agents and nicotinic acetylcholine receptor modulators for treating dopaminergic-related disorders
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
US20160250224A1 (en) 2013-09-24 2016-09-01 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
US10172916B2 (en) 2013-11-15 2019-01-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
US9815787B2 (en) 2013-12-12 2017-11-14 University Of Tsukuba Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
WO2015147240A1 (ja) 2014-03-28 2015-10-01 国立大学法人筑波大学 敗血症の予防治療剤
US10221170B2 (en) 2014-08-13 2019-03-05 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
EP3029024A1 (en) 2014-12-02 2016-06-08 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
JP6746107B2 (ja) 2015-02-19 2020-08-26 国立大学法人 筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
KR20240051297A (ko) 2015-03-24 2024-04-19 파라테크 파마슈티컬스, 인크. 생물방어를 위한 미노시클린 화합물
EP3309146A4 (en) 2015-06-12 2019-02-27 University of Tsukuba SULPHONAMID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITIVE SALT THEREOF
US10980755B2 (en) 2015-09-10 2021-04-20 The Regents Of The University Of California LRH-1 modulators
RS62861B1 (sr) 2016-02-04 2022-02-28 Takeda Pharmaceuticals Co Supstituisano piperidin jedinjenje i njegova upotreba
JP7012703B2 (ja) 2017-03-08 2022-02-14 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
WO2018164191A1 (ja) 2017-03-08 2018-09-13 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
WO2019027058A1 (en) * 2017-08-03 2019-02-07 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND AND USE THEREOF
EP3663281B1 (en) 2017-08-03 2022-12-28 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
WO2019112007A1 (ja) 2017-12-07 2019-06-13 国立大学法人 筑波大学 鎮痛薬による眠気の予防または治療薬
JP7339250B2 (ja) 2018-06-29 2023-09-05 武田薬品工業株式会社 複素環化合物およびその用途
US11655241B2 (en) 2018-06-29 2023-05-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP3895707B1 (en) 2018-12-12 2023-10-04 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP7408569B2 (ja) 2018-12-12 2024-01-05 武田薬品工業株式会社 複素環化合物
JP7662519B2 (ja) 2018-12-20 2025-04-15 ケーエスキュー セラピューティクス， インコーポレイテッド 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤としてのそれらの使用
MY210283A (en) 2019-01-31 2025-09-08 Pfizer 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
IL284073B2 (he) 2019-01-31 2025-07-01 Takeda Pharmaceuticals Co תרכובת הטרוציקלית ומלח שלה, תרופה, והתרכובת או המלח לשימוש במניעת או בטיפול בנרקולפסיה
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
US12331018B2 (en) 2019-02-13 2025-06-17 Merck Sharp & Dohme Llc Pyrrolidine orexin receptor agonists

Also Published As

Publication number Publication date
US20250243156A1 (en) 2025-07-31
EA202192138A1 (ru) 2022-03-10
US12415782B2 (en) 2025-09-16
AU2020215380A2 (en) 2021-08-19
TWI832962B (zh) 2024-02-21
KR20210121080A (ko) 2021-10-07
US12421188B2 (en) 2025-09-23
PH12021551846A1 (en) 2022-05-23
HRP20250785T1 (hr) 2025-09-12
PL3917616T3 (pl) 2025-09-08
SI3917616T1 (sl) 2025-08-29
CN118420600A (zh) 2024-08-02
CN113395993A (zh) 2021-09-14
MY209784A (en) 2025-08-04
CN118271297A (zh) 2024-07-02
IL284073A (he) 2021-08-31
RS67170B1 (sr) 2025-09-30
ES3037650T3 (en) 2025-10-03
PE20211700A1 (es) 2021-09-01
ZA202106304B (en) 2023-06-28
JP2023078426A (ja) 2023-06-06
CN118271298A (zh) 2024-07-02
US20230040770A1 (en) 2023-02-09
JP7253640B2 (ja) 2023-04-06
DK3917616T3 (da) 2025-07-21
AU2020215380B2 (en) 2025-09-25
US20250243158A1 (en) 2025-07-31
ECSP21056325A (es) 2021-09-30
US11028048B2 (en) 2021-06-08
US20210276949A1 (en) 2021-09-09
US20200247747A1 (en) 2020-08-06
LT3917616T (lt) 2025-08-11
PT3917616T (pt) 2025-08-28
MX2021008241A (es) 2021-08-16
EP4578853A2 (en) 2025-07-02
KR102882779B1 (ko) 2025-11-07
EP3917616A1 (en) 2021-12-08
AR117916A1 (es) 2021-09-01
IL284073B1 (he) 2025-03-01
EP3917616B1 (en) 2025-06-11
BR112021014180A2 (pt) 2021-09-21
SG11202106791XA (en) 2021-07-29
US12404237B2 (en) 2025-09-02
CO2021011188A2 (es) 2021-10-29
CN113395993B (zh) 2024-02-20
EP4578853A3 (en) 2025-09-03
CA3124536A1 (en) 2020-08-06
JP2022519331A (ja) 2022-03-22
FI3917616T3 (fi) 2025-07-24
HUE071890T2 (hu) 2025-09-28
US20240360080A1 (en) 2024-10-31
CN118344346A (zh) 2024-07-16
CN118290408A (zh) 2024-07-05
TW202043196A (zh) 2020-12-01
WO2020158958A1 (en) 2020-08-06
AU2020215380A1 (en) 2021-08-19
JP7502512B2 (ja) 2024-06-18
US20250243157A1 (en) 2025-07-31
CL2021001973A1 (es) 2022-04-08

Similar Documents

Publication Publication Date Title
IL284073B2 (he) תרכובת הטרוציקלית ומלח שלה, תרופה, והתרכובת או המלח לשימוש במניעת או בטיפול בנרקולפסיה
RU2495044C2 (ru) Ингибиторы активности протеинтирозинкиназы
CA3187297A1 (en) Active compound combinations
RU2486181C2 (ru) Пиримидилциклопентаны как ингибиторы акт-протеинкиназ
RU2363700C2 (ru) Производные хинуклидина и фармацевтические композиции, содержащие их
PH12020552263A1 (en) Prophylactic or therapeutic agent for spinal muscular atrophy
IL258073A (he) תרכובות ותולדות ספירו[3h-אינדול-2,3'-פירולידין]-2-(1h)-און כמעכבי mdm2-p53
CR20200588A (es) Compuestos novedosos
FI3853234T3 (fi) Fuusioituja trisyklisiä rengasjohdannaisia SRC-homologia-2-fosfataasin estäjinä
JP2016536363A5 (he)
MX2020007532A (es) Inhibidores de sarcomero cardiaco.
JP2016536364A5 (he)
MX348084B (es) Compuestos de cetolido.
JP2017523997A5 (he)
MX2021004762A (es) Compuesto (hetero)arilimidazol y agente de control de organismos nocivos.
JP2017537882A5 (he)
SG174582A1 (en) Hepatitis c virus inhibitors
JP2016504378A5 (he)
JP2018509418A5 (he)
RU2015108898A (ru) 3-ЦИКЛОГЕКСЕНИЛ И ЦИКЛОГЕКСИЛ ЗАМЕЩЕННЫЕ ИНДОЛЬНЫЕ И ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORгаммаТ И ИХ ПРИМЕНЕНИЯ
NZ630259A (en) Heterobicyclic compounds as beta-lactamase inhibitors
NO20070343L (no) N-(1 -(1 -benzyl-4-fenyl-1 H-imidazol-2-yl)-2,2-dimetylpropyl)benzamid derivater og relaterte forbindelser som kinesin spindelprotein (KSP) inhibitorer for behandling av kreft
RU2010101004A (ru) Новые микробиоциды
DE60103136D1 (de) Imidazol derivate als raf kinase inhibitoren
MX2023010125A (es) Inhibidores del sarcomero cardiaco.